The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions
Open accessAbstract
Patient-centered decision making about hot flash treatments often incorporates a balance of efficacy and side effects in addition to patient preference. This systematic review examines randomized controlled trials (RCTs) comparing at least two non-hormonal hot flash treatments in breast cancer survivors. In July 2015, PubMed, SCOPUS, CINAHL, Cochrane, and Web of Science databases were searched for RCTs comparing active, non-hormonal hot flash treatments in female breast cancer survivors. Thirteen trials were included after identifying 906 potential studies. Four trials were dose comparison studies of pharmacologic treatments citalopram, venlafaxine, gabapentin, and paroxetine. Hot flash reduction did not differ by tamoxifen or aromatase inhibitor use. Citalopram 10, 20, and 30 mg daily had comparable outcomes. Venlafaxine 75 mg daily improved hot flashes without additional side effects from higher dosing. Gabapentin 900 mg daily improved hot flashes more than 300 mg. Paroxetine 10 mg daily had fewer side effects than 20 mg. Among four trials comparing different pharmacologic treatments, venlafaxine alleviated hot flash symptoms faster than clonidine; participants preferred venlafaxine over gabapentin. Five trials compared pharmacologic to non-pharmacologic treatments. Acupuncture had similar efficacy to venlafaxine and gabapentin but may have longer durability after completing treatment and fewer side effects. We could not perform a pooled meta-analysis because outcomes were not reported in comparable formats. Clinical trial data on non-hormonal hot flash treatments provide comparisons of hot flash efficacy and other patient important outcomes to guide clinical management. Clinicians can use the information to help patients select hot flash interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To control hot flushes, valid alternatives are venlafaxine, oxybutynin, gabapentin and clonidine.118, 119, 120, 121”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [119]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042 · cited 1×
“This systematic review was conducted in accordance with PRISMA guidelines [30].”
MethodThe CES-D Scale: A Self-Report Depression Scale for Research in the General Population
Radloff, L. S. (1977) · Applied Psychological Measurement · doi:10.1177/014662167700100306 · Cited by 53,267
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research
Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90047-4 · Cited by 35,234 · cited 2×
“Additional effects (Pittsburgh Sleep Quality Index [57], Menopausal Rating Scale [58])”
BackgroundInfluentialThe Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
WARE, J. E., KOSINSKI, M., & KELLER, S. D. (1996) · Medical Care · doi:10.1097/00005650-199603000-00003 · Cited by 17,392
Research works printed but not linked: 2
- Stewart AL, Ware JE (1992) Measuring Function and Well Being: The Medical Outcomes Study Approach. Duke University Press, Durham
- Meijman TF, de Vries-Griever AH, de Vries G (1988) The evaluation of the Groningen sleep quality scale. Heymans Bulletin (HB 88-13-EX), Groningen
Cited by
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369
“To control hot flushes, valid alternatives are venlafaxine, oxybutynin, gabapentin and clonidine.(118-121) Sleep disturbances may be treated with melatonin.”
BackgroundSurvivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Denlinger, C. S., Sanft, T. B., Baker, K. S., Baxi, S. S., Broderick, G. A., Demark‐Wahnefried, W., Friedman, D. L., Goldman, M. E., Hudson, M. M., Khakpour, N., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0146 · Cited by 176
Zia, F. Z., Olaku, O. O., Bao, T., Berger, A. M., Deng, G., Fan, A. Y., Garcia, M. K., Herman, P. M., Kaptchuk, T. J., Ladas, E. J., et al. (2017) · JNCI Monographs · doi:10.1093/jncimonographs/lgx005 · Cited by 143
“Non–hormonally based drugs such as venlafaxine, gabapentin, citalopram, and clonidine have shown benefit, but have also shown considerable side effects (40).”
BackgroundSelf-citation
Metadata
- Authors
- Johns, C., Seav, S. M., Dominick, S. A., Gorman, J. R., Li, H., Natarajan, L., Mao, J. J., & Irene Su, H.
- Affiliations
- University of California, San Francisco (US)
- University of California San Diego (US)
- Oregon State University (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Venue
- Breast Cancer Research and Treatment
- Published
- 2016-03-26
- Volume
- 156
- Issue
- 3
- Pages
- 415-426
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- PMC
- PMC4838539
- OpenAlex
- W2310666724
- Cited by
- 72
- References
- 63
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 1 · 2023: 5 · 2022: 9 · 2021: 8 · 2020: 9 · 2019: 12 · 2018: 10 · 2017: 7 · 2016: 7
- FWCI
- 1.77
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Breast Cancer Research and Treatment (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- California Breast Cancer Research Program (200B-0 144)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
- Keywords
- hot flashes, breast cancer survivors, venlafaxine, gabapentin, paroxetine, citalopram, clonidine, acupuncture, aromatase inhibitors, tamoxifen, patient-centered decision-making, dose comparison, adverse effects
- MeSH terms
- Serotonin and Noradrenaline Reuptake Inhibitors, Breast Neoplasms, Female, Humans, Randomized Controlled Trials as Topic, Treatment Outcome, Survivors, Evidence-Based Medicine, Disease Management, Hot Flashes, Patient Preference
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions. https://app.cochat.ai/papers/10.1007/s10549-016-3765-4
- The paper
- Johns, C., Seav, S. M., Dominick, S. A., Gorman, J. R., Li, H., Natarajan, L., Mao, J. J., & Irene Su, H. (2016). Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-016-3765-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.